Contingency Fees

Investors File Suit After Embecta’s May 5 Disclosure Triggered 57.8% Stock Drop

Plaintiffs say Embecta misrepresented the basis for its Q2 and full‑year 2026 guidance by downplaying concentrated customer losses and retail weakness in its insulin pen and pen‑needle business.